| Wave Life Sciences Ltd. |
10%+ Owner |
Ordinary Shares |
18.2M |
$347M |
$19.00 |
11 Dec 2025 |
By Corporation |
| Lyell Immunopharma, Inc. |
10%+ Owner |
Common Stock |
30.3M |
$69M |
$2.28 |
21 Jun 2021 |
Indirect |
| CVRx, Inc. |
10%+ Owner |
Common Stock |
1.01M |
$18.7M |
$18.55 |
02 Jul 2021 |
Indirect |
| Spero Therapeutics, Inc. |
10%+ Owner |
Common Stock |
9.19M |
$11.7M |
$1.27 |
07 Nov 2022 |
Indirect |
| CVRx, Inc. |
10%+ Owner |
Series B-2 Preferred Stock |
0 |
|
|
02 Jul 2021 |
Indirect |
| CVRx, Inc. |
10%+ Owner |
Series C-2 Preferred Stock |
0 |
|
|
02 Jul 2021 |
Indirect |
| CVRx, Inc. |
10%+ Owner |
Series D-2 Preferred Stock |
0 |
|
|
02 Jul 2021 |
Indirect |
| CVRx, Inc. |
10%+ Owner |
Series E-2 Preferred Stock |
0 |
|
|
02 Jul 2021 |
Indirect |
| CVRx, Inc. |
10%+ Owner |
Series F-2 Preferred Stock |
0 |
|
|
02 Jul 2021 |
Indirect |
| CVRx, Inc. |
10%+ Owner |
Series G Preferred Stock |
0 |
|
|
02 Jul 2021 |
Indirect |
| Innoviva, Inc. |
10%+ Owner |
Common Stock |
0 |
|
$16.05 |
20 May 2021 |
Indirect |
| Lyell Immunopharma, Inc. |
10%+ Owner |
Series AA Preferred Stock |
0 |
|
|
21 Jun 2021 |
Indirect |
| Theravance Biopharma, Inc. |
Former 10% Owner |
Ordinary Shares |
0 |
|
$10.29 |
16 Sep 2022 |
By Corporation |
| Theravance Biopharma, Inc. |
Former 10% Owner |
Exchangeable Senior Notes due 2023 |
0 |
|
|
16 Sep 2022 |
Indirect |